EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long‐term outcome in locally advanced rectal cancer

Ross K McMahon iD, Sean M O'Cathail, Harikrishnan Nair, Colin W Steele, Jonathan J Platt, Michael Digby, Alec C McDonald, Paul G Horgan, Campbell S D Roxburgh

Colorectal Disease · 2023

DOI: 10.1111/codi.16667 ↗

At a glance

Journal article in Colorectal Disease, 2023. Written by Ross K McMahon and 8 co-authors. Institution: Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Major MEDLINE topics: Rectal Neoplasms, Neoplasms, Second Primary. Cited 3 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cancer Research UK, Chief Scientist Office.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

Neoadjuvant rectal (NAR) score is an early surrogate for longer‐term outcomes in rectal cancer undergoing radiotherapy and resection. In an era of increasing organ preservation, resection specimens are not always available to calculate the NAR score. Post‐treatment magnetic resonance imaging (MRI) re‐staging of regression is subjective, limiting reproducibility. We explored the potential for a novel MRI‐based NAR score (mrNAR) adapted from the NAR formula.

Methods

Locally advanced rectal cancer patients undergoing neoadjuvant therapy (nCRT) and surgery were retrospectively identified between 2008 and 2020 in a single cancer network. mrNAR was calculated by adapting the NAR formula, replacing pathological (p) stages with post‐nCRT MR stages ( ymr ). Cox regression assessed relationships between clinicopathological characteristics, NAR and mrNAR with overall survival (OS) and recurrence‐free survival (RFS).

Results

In total, 381 NAR and 177 mrNAR scores were calculated. On univariate analysis NAR related to OS (hazard ratio [HR] 2.05, 95% confidence interval [CI] 1.33–3.14, p = 0.001) and RFS (HR 2.52, 95% CI 1.77–3.59, p = 0.001). NAR 3‐year OS 16 was 80%. mrNAR related to OS (HR 2.96, 95% CI 1.38–6.34, p = 0.005) and RFS (HR 2.99, 95% CI 1.49–6.00, p = 0.002). 3‐year OS for mrNAR 16 was 78%. On multivariate analysis, mrNAR was a stage‐independent predictor of OS and RFS. mrNAR corresponded to NAR score category in only 15% (positive predictive value 0.23) and 47.5% (positive predictive value 0.48) of cases for categories 16, respectively.

Conclusions

Neoadjuvant rectal score is validated as a surrogate end‐point for long‐term outcomes. mrNAR categories do not correlate with NAR but have stage‐independent prognostic value. mrNAR may represent a novel surrogate end‐point for future neoadjuvant treatments that focus on organ preservation.

Subjects

MeSH terms (MEDLINE)

Rectal NeoplasmsNeoplasms, Second PrimaryHumansNeoadjuvant TherapyRetrospective StudiesReproducibility of ResultsPrognosisChemoradiotherapyChemoradiotherapy, AdjuvantBiomarkersMagnetic Resonance ImagingTreatment OutcomeNeoplasm Staging

Author keywords

LARCMRINAR scorecCRclinical complete responsemrNAR scoreneoadjuvantorgan preservationpCRpathological complete responserectal cancersurrogate end-pointwatch and wait

Substances

Biomarkers

Authors and institutions

  • Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Radiology/Imaging Department, Glasgow Royal Infirmary, Glasgow, UK.
  • Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Academic Unit of Surgery, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

ORCID profiles: Ross K McMahon

Funding

  • Cancer Research UK
  • Chief Scientist Office

Cite

APA

McMahon, R. K., O'Cathail, S. M., Nair, H., Steele, C. W., Platt, J. J., Digby, M., McDonald, A. C., Horgan, P. G., & Roxburgh, C. S. D. (2023). The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long‐term outcome in locally advanced rectal cancer. Colorectal Disease. https://doi.org/10.1111/codi.16667

Vancouver

McMahon RK, O'Cathail SM, Nair H, Steele CW, Platt JJ, Digby M, et al. The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long‐term outcome in locally advanced rectal cancer. Colorectal Disease. 2023. doi:10.1111/codi.16667

BibTeX
@article{McMahon2023,
  author = {McMahon, Ross K and O'Cathail, Sean M and Nair, Harikrishnan and Steele, Colin W and Platt, Jonathan J and Digby, Michael and McDonald, Alec C and Horgan, Paul G and Roxburgh, Campbell S D},
  title = {The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long‐term outcome in locally advanced rectal cancer},
  journal = {Colorectal Disease},
  year = {2023},
  doi = {10.1111/codi.16667}
}
Start for free →